BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to post its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.07) per share and revenue of $130.05 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $9.21 on Friday. The stock’s 50 day simple moving average is $8.01 and its 200 day simple moving average is $7.84. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The company has a market cap of $1.91 billion, a P/E ratio of -15.10 and a beta of 1.75.

Analysts Set New Price Targets

Several brokerages recently weighed in on BCRX. Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays lifted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.